The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Related articles in The JI
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by He, Y.
Right arrow Articles by Jiang, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by He, Y.
Right arrow Articles by Jiang, S.
The Journal of Immunology, 2006, 176: 6085-6092.
Copyright © 2006 by The American Association of Immunologists

Cross-Neutralization of Human and Palm Civet Severe Acute Respiratory Syndrome Coronaviruses by Antibodies Targeting the Receptor-Binding Domain of Spike Protein

Yuxian He1,*, Jingjing Li*, Wenhui Li{dagger}, Sara Lustigman*, Michael Farzan{dagger} and Shibo Jiang*

* Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021; and {dagger} Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center, Southborough, MA 01772

The spike (S) protein of severe acute respiratory syndrome coronavirus (SARS-CoV) is considered as a protective Ag for vaccine design. We previously demonstrated that the receptor-binding domain (RBD) of S protein contains multiple conformational epitopes (Conf I-VI) that confer the major target of neutralizing Abs. Here we show that the recombinant RBDs derived from the S protein sequences of Tor2, GD03, and SZ3, the representative strains of human 2002–2003 and 2003–2004 SARS-CoV and palm civet SARS-CoV, respectively, induce in the immunized mice and rabbits high titers of cross-neutralizing Abs against pseudoviruses expressing S proteins of Tor2, GD03, and SZ3. We also demonstrate that the Tor2-RBD induced-Conf I-VI mAbs can potently neutralize both human SARS-CoV strains, Tor2 and GD03. However, only the Conf IV-VI, but not Conf I-III mAbs, neutralize civet SARS-CoV strain SZ3. All these mAbs reacted significantly with each of the three RBD variants (Tor2-RBD, GD03-RBD, and SZ3-RBD) that differ at several amino acids. Regardless, the Conf I-IV and VI epitopes were completely disrupted by single-point mutation of the conserved residues in the RBD (e.g., D429A, R441A, or D454A) and the Conf III epitope was significantly affected by E452A or D463A substitution. Interestingly, the Conf V epitope, which may overlap the receptor-binding motif and induce most potent neutralizing Abs, was conserved in these mutants. These data suggest that the major neutralizing epitopes of SARS-CoV have been apparently maintained during cross-species transmission, and that RBD-based vaccines may induce broad protection against both human and animal SARS-CoV variants.


Related articles in The JI:

IN THIS ISSUE

The JI 2006 176: 5699-5700. [Full Text]  



This article has been cited by other articles:


Home page
 J. Immunol.Home page
Y. He, S. J. Barker, A. J. MacDonald, Y. Yu, L. Cao, J. Li, R. Parhar, S. Heck, S. Hartmann, D. T. Golenbock, et al.
Recombinant Ov-ASP-1, a Th1-Biased Protein Adjuvant Derived from the Helminth Onchocerca volvulus, Can Directly Bind and Activate Antigen-Presenting Cells
J. Immunol., April 1, 2009; 182(7): 4005 - 4016.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. Sheahan, B. Rockx, E. Donaldson, D. Corti, and R. Baric
Pathways of Cross-Species Transmission of Synthetically Reconstructed Zoonotic Severe Acute Respiratory Syndrome Coronavirus
J. Virol., September 1, 2008; 82(17): 8721 - 8732.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
B. Rockx, D. Corti, E. Donaldson, T. Sheahan, K. Stadler, A. Lanzavecchia, and R. Baric
Structural Basis for Potent Cross-Neutralizing Human Monoclonal Antibody Protection against Lethal Human and Zoonotic Severe Acute Respiratory Syndrome Coronavirus Challenge
J. Virol., April 1, 2008; 82(7): 3220 - 3235.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
V. C. C. Cheng, S. K. P. Lau, P. C. Y. Woo, and K. Y. Yuen
Severe Acute Respiratory Syndrome Coronavirus as an Agent of Emerging and Reemerging Infection
Clin. Microbiol. Rev., October 1, 2007; 20(4): 660 - 694.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
Z. Zhu, S. Chakraborti, Y. He, A. Roberts, T. Sheahan, X. Xiao, L. E. Hensley, P. Prabakaran, B. Rockx, I. A. Sidorov, et al.
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies
PNAS, July 17, 2007; 104(29): 12123 - 12128.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
B. Rockx, T. Sheahan, E. Donaldson, J. Harkema, A. Sims, M. Heise, R. Pickles, M. Cameron, D. Kelvin, and R. Baric
Synthetic Reconstruction of Zoonotic and Early Human Severe Acute Respiratory Syndrome Coronavirus Isolates That Produce Fatal Disease in Aged Mice
J. Virol., July 15, 2007; 81(14): 7410 - 7423.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
L. Liu, Q. Fang, F. Deng, H. Wang, C. E. Yi, L. Ba, W. Yu, R. D. Lin, T. Li, Z. Hu, et al.
Natural Mutations in the Receptor Binding Domain of Spike Glycoprotein Determine the Reactivity of Cross-Neutralization between Palm Civet Coronavirus and Severe Acute Respiratory Syndrome Coronavirus
J. Virol., May 1, 2007; 81(9): 4694 - 4700.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2006 by The American Association of Immunologists, Inc. All rights reserved.